Nanozymes for Liver Disease Therapy: Advances in Catalytic Activity, Targeting Strategies, and Clinical Translation
Advanced Science · 2026
DOI: 10.1002/advs.74590 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, 2026. Verfasst von Xiandi Meng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Cha…. Hauptthemen laut MEDLINE: Liver Diseases, Nanostructures, Drug Delivery Systems, Enzymes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 217 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Science and technology research project of the Education Department of Jilin Province.
Abstract (Originalsprache)
Natural and artificial enzymes have emerged as promising candidates for biomedical applications, possessing the potential to address redox imbalances and metabolic disorders in liver diseases. However, their clinical translation remains limited by challenges in biocompatibility, targeted delivery, dose‐response balance, and long‐term stability. Nanozymes, novel nanomaterials with potent enzyme‐like catalytic activity, exhibit promising capacities to overcome these challenges. In this review, we discuss nanozymes applied to liver diseases, including metabolic disorders, tissue repair, hepatic tumors, and viral infections. Under physiological and pathological liver conditions, diverse targeting strategies can be applied for the precise delivery of nanozymes. We demonstrate the fundamental mechanisms of nanozymes in scavenging reactive oxygen species (ROS), alleviating oxidative stress, and remodeling the immune microenvironment. The structural features, including size, morphology, composition, and surface modifications of nanozymes, critically influence catalytic performance and targeting efficiency at disease sites. These design criteria improve catalytic activity and reduce drug‐induced toxicity, thereby achieving a balance between dosage and therapeutic effects. We highlight the Artificial Intelligence (AI)‐driven revolution, in which machine learning contributes to predicting catalytic activity, optimizing structural design, and enabling intelligent applications of nanozymes. Finally, we outline the potential strategies and the limitations of nanozymes for clinical translation in liver disease therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China.
- National-local Joint Engineering Laboratory of Animal Models for Human Diseases, Changchun, Jilin, China.
- Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
- International Center of Future Science, Jilin University, Changchun, Jilin, China.
- State Key Laboratory of Supramolecular Structure and Materials, Jilin University, Changchun, Jilin, China.
ORCID-Profile: Yong-Guang Yang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Science and technology research project of the Education Department of Jilin Province
- Fundamental Research Funds for the Central Universities
- Jilin University
Zitieren
APA
Meng, X., Zhu, G., Sun, S., Yao, W., Zhang, Y., Yang, Y. G., & Sun, T. (2026). Nanozymes for Liver Disease Therapy: Advances in Catalytic Activity, Targeting Strategies, and Clinical Translation. Advanced Science. https://doi.org/10.1002/advs.74590
Vancouver
Meng X, Zhu G, Sun S, Yao W, Zhang Y, Yang YG, et al. Nanozymes for Liver Disease Therapy: Advances in Catalytic Activity, Targeting Strategies, and Clinical Translation. Advanced Science. 2026. doi:10.1002/advs.74590
BibTeX
@article{Meng2026,
author = {Meng, Xiandi and Zhu, Ge and Sun, Siyu and Yao, Wenbo and Zhang, Yuning and Yang, Yong-Guang and Sun, Tianmeng},
title = {Nanozymes for Liver Disease Therapy: Advances in Catalytic Activity, Targeting Strategies, and Clinical Translation},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.74590}
}
EUVIMED